Health and Me

Ishita Roy

Weight Loss Drugs Could Now Cut Stroke Risk, Finds Study

A new meta-analysis published in the journal <em><span rel="noindex">Stroke</span> </em>reports that GLP-1 receptor agonists such as <span>semaglutide</span> may help reduce the risk of ischemic stroke in patients who do not have diabetes. The findings come from a review of preclinical studies and highlight the growing interest in how these widely used drugs may offer benefits beyond blood sugar control.

<h2>What GLP-1 Drugs Are and How They Work</h2>

GLP-1 receptor agonists are a class of medications that mimic a natural hormone called glucagon-like peptide-1. This hormone helps regulate appetite, insulin release and blood sugar levels. Drugs in this category include semaglutide, liraglutide, exenatide, lixisenatide and dulaglutide. Semaglutide is sold under the brand names Wegovy and Ozempic.

These medicines were originally developed for people with type 2 diabetes. Over time, scientists observed additional effects such as reduced appetite, improved metabolic markers and modest cardiovascular protection. This led to their approval for weight management in people without diabetes. Today, GLP-1 drugs are among the most prescribed medications for obesity and are being studied for heart failure, kidney disease and other conditions. However, their potential benefits in non-diabetic patients at risk of stroke remain largely unexplored.

Researchers from Aarhus University in Denmark conducted the meta-analysis to understand whether GLP-1 drugs could reduce the severity or likelihood of acute ischemic stroke in people who do not have diabetes. The team examined 31 preclinical trials conducted between 2011 and 2024. All studies were carried out in rodent models.

The included drugs were given either orally or through subcutaneous injections. The researchers compared animals receiving GLP-1 drugs with those given a placebo. They reviewed outcomes such as infarct volume, neurological recovery and markers of cell injury.

<h2>Findings Show Promising Neuroprotective Effects</h2>

Across the studies, animals treated with GLP-1 drugs showed significantly smaller infarct volumes than those given a placebo. They also demonstrated better neurological function after stroke.

Lead author Michael K. Michaelsen from the department of clinical medicine at Aarhus University wrote that the mechanisms behind these benefits are not yet clear. He noted that the effects appear to extend beyond blood sugar regulation. According to the paper, GLP-1 drugs may act on multiple pathways involved in stroke injury including inflammation, oxidative stress and cell death. The authors observed reductions in oxidative stress markers, inflammatory mediators and indicators of cell death in several trials. However, they cautioned that these findings do not prove causality.

Since all the analyzed studies were in animals, experts say it is too early to conclude whether GLP-1 receptor agonists could improve stroke outcomes in non-diabetic patients. Clinical trials will be needed to confirm whether the neuroprotective effects translate to humans.

The authors noted that if future research shows that these drugs do not affect platelet function or clotting during the acute phase of stroke, they could one day be used even before patients undergo neuroimaging. They wrote that early prehospital administration could potentially offer faster protection during the critical first moments of stroke.

Health Conditions A-Z

health

semagutide can reduce stroke risk

stroke

health and wellness

heart heALTH

brain health

semaglutide

The Invisible Weight of Suicide Loss: Stories of Guilt, Love, and Healing

Living In Delhi's Toxic Air Is A 'Medical Emergency', According AIIMS Doctors

Health & Wellness

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

A new meta-analysis published in the journal Stroke reports that GLP-1 receptor agonists such as semaglutide may help reduce the risk of ischemic stroke in patients who do not have diabetes. The findings come from a review of preclinical studies and highlight the growing interest in how these widely used drugs may offer benefits beyond blood sugar control.What GLP-1 Drugs Are and How They WorkGLP-1 receptor agonists are a class of medications that mimic a natural hormone called glucagon-like peptide-1. This hormone helps regulate appetite, insulin release and blood sugar levels. Drugs in this category include semaglutide, liraglutide, exenatide, lixisenatide and dulaglutide. Semaglutide is sold under the brand names Wegovy and Ozempic.These medicines were originally developed for people with type 2 diabetes. Over time, scientists observed additional effects such as reduced appetite, improved metabolic markers and modest cardiovascular protection. This led to their approval for weight management in people without diabetes. Today, GLP-1 drugs are among the most prescribed medications for obesity and are being studied for heart failure, kidney disease and other conditions. However, their potential benefits in non-diabetic patients at risk of stroke remain largely unexplored.What the New Review ExaminedResearchers from Aarhus University in Denmark conducted the meta-analysis to understand whether GLP-1 drugs could reduce the severity or likelihood of acute ischemic stroke in people who do not have diabetes. The team examined 31 preclinical trials conducted between 2011 and 2024. All studies were carried out in rodent models.The included drugs were given either orally or through subcutaneous injections. The researchers compared animals receiving GLP-1 drugs with those given a placebo. They reviewed outcomes such as infarct volume, neurological recovery and markers of cell injury.Findings Show Promising Neuroprotective EffectsAcross the studies, animals treated with GLP-1 drugs showed significantly smaller infarct volumes than those given a placebo. They also demonstrated better neurological function after stroke.Lead author Michael K. Michaelsen from the department of clinical medicine at Aarhus University wrote that the mechanisms behind these benefits are not yet clear. He noted that the effects appear to extend beyond blood sugar regulation. According to the paper, GLP-1 drugs may act on multiple pathways involved in stroke injury including inflammation, oxidative stress and cell death. The authors observed reductions in oxidative stress markers, inflammatory mediators and indicators of cell death in several trials. However, they cautioned that these findings do not prove causality.Human Impact Still UnknownSince all the analyzed studies were in animals, experts say it is too early to conclude whether GLP-1 receptor agonists could improve stroke outcomes in non-diabetic patients. Clinical trials will be needed to confirm whether the neuroprotective effects translate to humans.The authors noted that if future research shows that these drugs do not affect platelet function or clotting during the acute phase of stroke, they could one day be used even before patients undergo neuroimaging. They wrote that early prehospital administration could potentially offer faster protection during the critical first moments of stroke.